ArticleFrontiers in pediatrics2026
Heparin continuous infusion for thromboprophylaxis in pediatric liver transplant recipients.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vascular thrombosis remains a significant cause of early graft loss and morbidity in pediatric liver transplant (PLT) patients. However, no standardized protocol for thromboprophylaxis exists. This study aimed to evaluate appropriateness of continuous infusion of unfractionated heparin (UFH) prophylaxis in PLT patients. Methods: This retrospective study was conducted in a pediatric intensive care unit. Patients between the ages of 1 month to 14 years who received prophylactic continuous UFH infusion following PLT were included. The primary outcome was to examine the percentage of patients on intravenous continuous UFH infusion achieving the prophylactic aPTT target levels (40-60 s) in PLT recipients whereas secondary outcomes were time to target, dose titrations, thrombotic events, bleeding complications and safety outcomes. Statistical analyses were performed using Stata software, version 18. For categorical variables, frequencies and percentages were used whereas continuous data was presented as median and interquartile range (IQR). Results: A total of 47 patients were included, with the majority constituting males (57.4%). Median heparin infusion duration was 55.93 h [38.97-79.97]. All patients achieved prophylactic aPTT target levels, with 89.4% reaching the target within 24 h. Median time to target achievement was 4.68 h [4.00-12.53]. Most patients (63.8%) achieved target prophylactic anticoagulation without dose titration whereas 6.4% required ≥3 titrations. Only 2 patients (4.3%) reported thrombotic complications including one portal vein thrombosis and one hepatic vein thrombosis. Clinically significant bleeding was reported in 7 patients (14.9%), with only one patient requiring surgical re-intervention. Hypotension was observed in 40.4% of patients. Median PICU length of stay was 4 days [3-6]. Conclusion: Postoperative thromboprophylaxis with continuous UFH infusion at an initial dose of 10 units/kg/hr was effective in achieving prophylactic anticoagulation in most PLT recipients. The protocol was associated with low thrombotic events and bleeding complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.